S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
The Next Big Crisis Is Here (Ad)
Japan firm opens whale meat vending machines to push sales
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
The Next Big Crisis Is Here (Ad)
Japan firm opens whale meat vending machines to push sales
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
The Next Big Crisis Is Here (Ad)
Japan firm opens whale meat vending machines to push sales
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
The Next Big Crisis Is Here (Ad)
Japan firm opens whale meat vending machines to push sales
Online system to seek asylum in US is quickly overwhelmed
NASDAQ:AMED

Amedisys - AMED Stock Forecast, Price & News

$93.18
+2.02 (+2.22%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$89.62
$93.39
50-Day Range
$80.12
$95.86
52-Week Range
$79.30
$179.91
Volume
215,397 shs
Average Volume
424,080 shs
Market Capitalization
$3.03 billion
P/E Ratio
25.12
Dividend Yield
N/A
Price Target
$128.25

Amedisys MarketRank™ Forecast

Analyst Rating
Hold
2.47 Rating Score
Upside/​Downside
37.6% Upside
$128.25 Price Target
Short Interest
Bearish
5.16% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.61
Upright™ Environmental Score
News Sentiment
0.24mentions of Amedisys in the last 14 days
Based on 17 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
2.07%
From $4.83 to $4.93 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.80 out of 5 stars

Medical Sector

52nd out of 1,055 stocks

Home Health Care Services Industry

4th out of 9 stocks


AMED stock logo

About Amedisys (NASDAQ:AMED) Stock

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care and palliative care to patients in their homes. As of December 31, 2021, the company owned and operated 331 home health care centers, 175 hospice care centers, and 14 personal-care, and 8 high acuity care centers in 38 states within the United States and the District of Columbia. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.

Receive AMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter.

AMED Stock News Headlines

Benchmark Trims Amedisys (NASDAQ:AMED) Target Price to $120.00
Amedisys (NASDAQ:AMED) Stock Rating Lowered by StockNews.com
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
StockNews.com Upgrades Amedisys (NASDAQ:AMED) to "Buy"
Amedisys: No Change To Thesis, Retain Hold
Amedisys Names Scott Ginn Acting Chief Operating Officer
Amedisys reaffirms FY22 guidance
Amedisys Third Quarter 2022 Earnings: Misses Expectations
See More Headlines
Receive AMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter.

AMED Company Calendar

Last Earnings
11/02/2021
Today
1/28/2023
Next Earnings (Estimated)
2/22/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Home health care services
Sub-Industry
Health Care Services
Sector
Medical
Current Symbol
NASDAQ:AMED
CUSIP
02343610
Employees
21,000
Year Founded
1982

Price Target and Rating

Average Stock Price Forecast
$128.25
High Stock Price Forecast
$190.00
Low Stock Price Forecast
$85.00
Forecasted Upside/Downside
+37.6%
Consensus Rating
Hold
Rating Score (0-4)
2.47
Research Coverage
15 Analysts

Profitability

Net Income
$209.07 million
Pretax Margin
7.47%

Debt

Sales & Book Value

Annual Sales
$2.21 billion
Cash Flow
$8.41 per share
Book Value
$29.95 per share

Miscellaneous

Free Float
31,810,000
Market Cap
$3.03 billion
Optionable
Optionable
Beta
0.96

Social Links


Key Executives

  • Mr. Paul Berthold Kusserow (Age 62)
    Chairman & CEO
    Comp: $1.1M
  • Mr. Scott G. GinnMr. Scott G. Ginn (Age 54)
    Exec. VP, CFO & Acting COO
    Comp: $779.31k
  • Mr. Pete Hartley
    CTO & Sr. VP of Bus. Operations Systems
  • Mr. Michael P. NorthMr. Michael P. North (Age 58)
    Chief Information Officer
  • Ms. Jennifer Guckert Griffin
    Sr. VP, Deputy Gen. Counsel, Corp. Sec. & Interim Chief Legal Officer
  • Ms. Denise BohnertMs. Denise Bohnert (Age 45)
    Chief Compliance Officer
  • Kendra Kimmons
    VP of Marketing & Communications & Media Relations
  • Mr. Adam Holton
    Chief People Officer
  • Mr. John Nugent
    Chief Acquisitions Officer
  • Ms. Janet Britt
    Sr. VP of Billing & Collections













AMED Stock - Frequently Asked Questions

Should I buy or sell Amedisys stock right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last twelve months. There are currently 2 sell ratings, 4 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AMED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMED, but not buy additional shares or sell existing shares.
View AMED analyst ratings
or view top-rated stocks.

What is Amedisys' stock price forecast for 2023?

15 analysts have issued 1 year price targets for Amedisys' shares. Their AMED share price forecasts range from $85.00 to $190.00. On average, they expect the company's stock price to reach $128.25 in the next twelve months. This suggests a possible upside of 37.6% from the stock's current price.
View analysts price targets for AMED
or view top-rated stocks among Wall Street analysts.

How have AMED shares performed in 2023?

Amedisys' stock was trading at $83.54 at the start of the year. Since then, AMED stock has increased by 11.5% and is now trading at $93.18.
View the best growth stocks for 2023 here
.

When is Amedisys' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our AMED earnings forecast
.

How were Amedisys' earnings last quarter?

Amedisys, Inc. (NASDAQ:AMED) announced its quarterly earnings results on Tuesday, November, 2nd. The health services provider reported $1.53 earnings per share for the quarter, beating the consensus estimate of $1.37 by $0.16. The health services provider earned $553.49 million during the quarter, compared to the consensus estimate of $568.55 million. Amedisys had a net margin of 5.45% and a trailing twelve-month return on equity of 16.00%. During the same period last year, the business posted $2.24 earnings per share.

How will Amedisys' stock buyback program work?

Amedisys declared that its Board of Directors has approved a share repurchase plan on Wednesday, August 4th 2021, which allows the company to buyback $100,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to buy up to 1.2% of its stock through open market purchases. Stock buyback plans are usually an indication that the company's board of directors believes its shares are undervalued.

What guidance has Amedisys issued on next quarter's earnings?

Amedisys issued an update on its FY 2022 earnings guidance on Sunday, December, 18th. The company provided earnings per share (EPS) guidance of $4.82-$4.93 for the period, compared to the consensus estimate of $4.87. The company issued revenue guidance of $2.22 billion-$2.23 billion, compared to the consensus revenue estimate of $2.23 billion.

What is Paul B. Kusserow's approval rating as Amedisys' CEO?

478 employees have rated Amedisys Chief Executive Officer Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among the company's employees. 60.0% of employees surveyed would recommend working at Amedisys to a friend.

What other stocks do shareholders of Amedisys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and Home Depot (HD).

What is Amedisys' stock symbol?

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Who are Amedisys' major shareholders?

Amedisys' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Riverbridge Partners LLC (4.70%), Assenagon Asset Management S.A. (0.22%), Bridge City Capital LLC (0.06%), Comerica Bank (0.04%), Park Avenue Securities LLC (0.02%) and Vestmark Advisory Solutions Inc. (0.02%). Insiders that own company stock include Bruce D Perkins, Bruce D Perkins, Christopher Gerard, David L Kemmerly, David L Kemmerly, Denise M Bohnert, Julie D Klapstein, Michael Paul North, Richard A Lechleiter, Scott G Ginn, Sharon Brunecz, Teresa L Kline and Vickie L Capps.
View institutional ownership trends
.

How do I buy shares of Amedisys?

Shares of AMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amedisys' stock price today?

One share of AMED stock can currently be purchased for approximately $93.18.

How much money does Amedisys make?

Amedisys (NASDAQ:AMED) has a market capitalization of $3.03 billion and generates $2.21 billion in revenue each year. The health services provider earns $209.07 million in net income (profit) each year or $3.71 on an earnings per share basis.

How many employees does Amedisys have?

The company employs 21,000 workers across the globe.

How can I contact Amedisys?

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The official website for the company is www.amedisys.com. The health services provider can be reached via phone at (225) 292-2031, via email at ir@amedisys.com, or via fax at 225-292-8163.

This page (NASDAQ:AMED) was last updated on 1/28/2023 by MarketBeat.com Staff